XCancer

Molecular Imaging of EpCam Expression in Breast Cancer Using [99mTc]Tc-DARPinEc1-G3C

Description:

The study should evaluate distribution of \[99mTc\]Tc-DARPinEc1-G3C in patients with primary Triple negative and Luminal breast cancer. The primary objective are: 1. To assess distribution of \[99mTc\]Tc-DARPinEc1-G3C in normal tissues and in tumors over time; 2. To evaluate dosimetry of \[99mTc\]Tc-DARPinEc1-G3C in breast cancer patients; 3. To obtain initial information concerning safety and tolerability of \[99mTc\]Tc-DARPinEc1-G3C in breast cancer patients after single intravenous injection: The secondary objective are: 1\. To compare the tumour imaging data with \[99mTc\]Tc-DARPinEc1-G3C in breast cancer patients with Triple negative and Luminal subtypes.

Sponsor:

Tomsk National Research Medical Center of the Russian Academy of Sciences

Phase:

Phase 1

Contacts:

Vladimir I. Chernov (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT07784660 - Click here to see study on

ClinicalTrials.gov

DARPinEc1-G3C

Isotope(s):
Target(s):
  • EpCAM
Ligand Class: Small Proteins and Antibody Fragments
Inclusion
  • Negative HER2 expression in primary tumour tissue according ASCO/CAP 2023 recommendation
  • ECOG 0-2.
  • Morphological verification of Breast Cancer T2-4N0-3M0-1
Exclusion
  • Active current autoimmune/infection disease or history of autoimmune disease. Known HIV positive or chronically active hepatitis B or C